Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1. CLL/SLL and have received all 5 classes of available therapy: chemotherapy, anti-cd-20 antibody, covalent Bruton’s Tyrosine Kinase (BTK) inhibitor, BCL-2 inhibitor and PI3K inhibitor;
    2. 2. MCL, who has been previously treated with a covalent BTK inhibitor, or Richter’s Transformation, who have had previous Richter’s directed-therapy
    3. 3. Waldenstrom macroglobulinemia (WM) patients who were previously treated with chemotherapy, anti-CD20 antibody, and a covalent BTK inhibitor.

You may not be eligible for this study if the following are true:

  • If you do not meet the inclusion criteria.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.